ASTRO对ASCO III期非小细胞肺癌管理指南的放射治疗摘要
美国放射肿瘤学会(ASTRO)基于ASCO III期非小细胞肺癌指南制定放射治疗摘要,由多学科专家组系统综述127篇文献并共识形成,聚焦新辅助、辅助和不可切除三种放疗情境,给出同步放化疗联合度伐利尤单抗巩固等推荐。
要点
- 计划手术的III期NSCLC应接受新辅助化疗或放化疗,N2或肺上沟瘤情境尤为重要。
- 完全切除的N2病变不常规推荐术后放疗;未接受新辅助化疗者应给辅助化疗。
- 不可切除者首选铂类双药同步放化疗60 Gy后度伐利尤单抗巩固。
核心结论
- 计划手术的III期NSCLC患者应接受新辅助化疗或放化疗,N2或肺上沟瘤情境加用新辅助治疗尤为重要。
- 术后未接受新辅助化疗者应接受辅助化疗;完全切除的N2病变不常规推荐术后放疗。
- 不可切除III期NSCLC理想管理为铂类双药同步放化疗、标准剂量60 Gy,初始治疗后无进展者接受度伐利尤单抗巩固。
- 不能耐受同步放化疗者可选择序贯化疗后放疗或剂量递增/大分割单纯放疗。
研究设计与样本
- ASCO、ASTRO和美国胸科医师学会召集多学科专家组,基于系统文献综述和正式共识流程制定指南。
- 由原指南放射肿瘤学家及ASTRO额外成员组成新专家组,为放射肿瘤学界提供进一步指导。
- 共127篇文章符合纳入标准,回答5个临床问题,本摘要聚焦新辅助、辅助和不可切除3个放疗问题。
主要发现
- 放射治疗特异性推荐被总结,并就术前放疗、术后放疗和联合放化疗的具体问题提供相关评论。
关键数值与推荐
- 计划手术的III期NSCLC:新辅助化疗或放化疗(推荐)。
- 完全切除的N2病变:不常规推荐术后放疗。
- 不可切除III期NSCLC:铂类双药同步放化疗,标准放疗剂量60 Gy,随后度伐利尤单抗巩固(推荐)。
- 不能耐受同步放化疗:序贯化疗后放疗或剂量递增/大分割单纯放疗(可考虑)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a radiation therapy summary of recommendations on the management of locally advanced non-small cell lung cancer (NSCLC) based on the Management of Stage III Non-Small Cell Lung Cancer: American Society of Clinical Oncology Guideline, which was endorsed by the American Society for Radiation Oncology (ASTRO). METHODS: The American Society of Clinical Oncology, ASTRO, and the American College of Chest Physicians convened a multidisciplinary panel to develop a guideline based on a systematic review of the literature and a formal consensus process, that has been separately published. A new panel consisting of radiation oncologists from the original guideline as well as additional ASTRO members was formed to provide further guidance to the radiation oncology community. A total of 127 articles met the eligibility criteria to answer 5 clinical questions. This summary focuses on the 3 radiation therapy questions (neoadjuvant, adjuvant, and unresectable settings). RESULTS: Radiation-specific recommendations are summarized with additional relevant commentary on specific questions regarding the management of preoperative radiation, postoperative radiation, and combined chemoradiation. CONCLUSIONS: Patients with stage III NSCLC who are planned for surgical resection, should receive either neoadjuvant chemotherapy or chemoradiation. The addition of neoadjuvant treatment is particularly important in patients planned for surgery in the N2 or superior sulcus settings. Postoperatively, patients who did not receive neoadjuvant chemotherapy should be offered adjuvant chemotherapy. The use of postoperative radiation for completely resected N2 disease is not routinely recommended. Unresectable patients with stage III NSCLC should ideally be managed with combined concurrent chemoradiation using a platinum-based doublet with a standard radiation dose of 60 Gy followed by consolidation durvalumab in patients without progression after initial therapy. Patients who cannot tolerate a concurrent chemoradiation approach can be managed either by sequential chemotherapy followed by radiation or by dose-escalated or hypofractionated radiation alone.
引用
- Simone CB, Bradley J, Chen AB, et al. ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2023. PMID: 37080641. doi:10.1016/j.prro.2023.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。